Introduction: Cutaneous manifestations of systemic sclerosis (SSc) include skin
ulceration; 4% - 12% of patients with SSc develop lower extremity ulcers of
various etiologies. Limited data, significant morbidity, and substantial cost
of wound care led us to undertake this study to describe and identify risk
factors. Methods: After Institutional Review Board approval, we
identified 30 patients with SSc and lower extremity ulcers over a 10-year
period at a single center with an SSc clinic, which were included in a
descriptive analysis. Results:
Median age of onset of lower extremity ulcers was 59.5 years (range 20 - 84).
Ninety percent of patients were female, 60% were Caucasian, 63% had limited
SSc, 13% diffuse SSc and 23% an overlap syndrome. Immunomodulators or steroids
were prescribed in 53%; hypercoagulable state identified in 16%. Ulcers were
attributed to venous stasis (27%), SSc (20%), trauma (20%), arterial disease
(17%), and multifactorial/unknown (17%). In patients with ulcers attributed to
SSc, age at onset was lower (45.5 vs 59.5 years). Biopsies generally did not
contribute to management. Multidisciplinary treatment was routine; 20% required
amputation, 10% endovascular intervention, 20% frequent surgical debridement,
10% hyperbaric oxygen, 26% local treatment and antibiotics and 13% received
immunosuppression for wound treatment. Conclusion: Lower extremity ulcers are a serious clinical problem in
patients with SSc. The clinical exam, venous dopplers, ankle-brachial indices
and assessment of vascular risk factors helped define causality. In younger
patients, ulcers were more frequently attributed to SSc and these patients were
more likely to be on immunosuppressants/DMARDS, possibly indicating severe
phenotype of SSc.
References
[1]
Gabrielli, A., Avvedimento, E.V. and Krieg, T. (2009) Scleroderma. The New England Journal of Medicine, 360, 1989-2003. https://doi.org/10.1056/NEJMra0806188
[2]
Strange, G. and Nash, P. (2009) The Manifestations of Vasculopathy in Systemic Sclerosis and Its Evidence-Based Therapy. International Journal of Rheumatic Diseases, 12, 192-206. https://doi.org/10.1111/j.1756-185X.2009.01410.x
[3]
Shanmugam, V.K., Price, P., Attinger, C.E. and Steen, V.D. (2010) Lower Extremity ULCERS in Systemic Sclerosis: Features and Response to Therapy. International Journal of Rheumatology, 2010, Article ID: 747946. https://doi.org/10.1155/2010/747946
[4]
Bohelay, G., Blaise, S., Levy, P., et al. (2018) Lower-Limb Ulcers in Systemic Sclerosis: A Multicentre Retrospective Case-control Study. Acta Dermato-Venereologica, 98, 677-682. https://doi.org/10.2340/00015555-2939
[5]
Blagojevic, J., Piemonte, G., Benelli, L., et al. (2016) Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist. The Journal of Rheumatology, 43, 592-598. https://doi.org/10.3899/jrheum.150035
[6]
Taniguchi, T., Asano, Y., Hatano, M., et al. (2012) Effects of Bosentan on Nondigital Ulcers in Patients with Systemic Sclerosis. British Journal of Dermatology, 166, 417-421. https://doi.org/10.1111/j.1365-2133.2011.10581.x
[7]
Nussbaum, S.R., Carter, M.J., Fife, C.E., et al. (2018) An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. Value Health, 21, 27-32. https://doi.org/10.1016/j.jval.2017.07.007
[8]
Merkel, P.A., Chang, Y., Pierangeli, S.S., Convery, K., Harris, E.N. and Polisson, R.P. (1996) The Prevalence and Clinical Associations of Anticardiolipin Antibodies in a Large Inception Cohort of Patients with Connective Tissue Diseases. The American Journal of Medicine, 101, 576-583. https://doi.org/10.1016/S0002-9343(96)00335-X
[9]
Schoenroth, L., Fritzler, M., Lonzetti, L. and Senécal, J.-L. (2002) Antibodies to Beta2 Glycoprotein I and Cardiolipin in SSc. Annals of the Rheumatic Diseases, 61, 183-184. https://doi.org/10.1136/ard.61.2.183-a